Credit Suisse’s Cytek Biosciences CTKB Stock Holding History

Credit Suisse’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	$627K	Hold	93,492	–	–	﹤0.01%	2532
2023 Q4	$853K	Buy	93,492 +19,510	+26%	+$123K	﹤0.01%	2436
2023 Q3	$408K	Buy	73,982 +4,457	+6%	+$35.8K	﹤0.01%	2791
2023 Q2	$594K	Buy	69,525 +15,136	+28%	+$136K	﹤0.01%	2688
2023 Q1	$500K	Buy	54,389 +16	+0%	+$172	﹤0.01%	2756
2022 Q4	$555K	Buy	54,373 +7,258	+15%	+$97.5K	﹤0.01%	2718
2022 Q3	$694K	Buy	47,115 +1,604	+4%	+$20.8K	﹤0.01%	2581
2022 Q2	$489K	Buy	+45,511	New	+$453K	﹤0.01%	2855

Other funds holding CTKB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Credit Suisse's CTKB Position: Q1 2024 in Review

Credit Suisse held its Cytek Biosciences (CTKB) position steady in Q1 2024 at 93,492 shares worth $627K. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

Credit Suisse first reported a position in CTKB in Q2 2022 and has held it in 8 quarters since. The position peaked at $853K in Q4 2023. 125 funds tracked by Wall St. Rank hold CTKB as of Q1 2024.

Credit Suisse held 93,492 shares of Cytek Biosciences worth $627K as of Q1 2024.
Credit Suisse left its Cytek Biosciences share count unchanged in Q1 2024.
Cytek Biosciences made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2532 holding.
Credit Suisse first reported a position in Cytek Biosciences in Q2 2022 and has held it in 8 quarters since.
Credit Suisse's Cytek Biosciences position peaked at $853K in Q4 2023.
125 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.